Design of fluorescent bradykinin analogs: Application to imaging of B 2 receptor-mediated agonist endocytosis and trafficking and angiotensin-converting enzyme

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 1, 2011, Pages 33-41

  Gera, Lajos ^a   Bawolak, Marie Thérèse ^b   Roy, Caroline ^b   Lodge, Robert ^c   Marceau, François ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 CARBOXYFLUORESCEIN; ADENOSINE TRIPHOSPHATASE; AMINOCAPROIC ACID; BETA ARRESTIN 1; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRILAT; KININASE; MEMBRANE PROTEIN; RAB PROTEIN; RAB5 PROTEIN; RAB7 PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CELL STRAIN HEK293; CELL TRANSPORT; CELL VACUOLE; CONTROLLED STUDY; CYTOSOL; EMBRYO; ENDOCYTOSIS; FLUORESCENCE ANALYSIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR BINDING; UMBILICAL VEIN; VENOCONSTRICTION;

BRADYKININ; DRUG DESIGN; ENDOCYTOSIS; FLUORESCENT DYES; HEK293 CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; ORGAN CULTURE TECHNIQUES; PEPTIDYL-DIPEPTIDASE A; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTOR, BRADYKININ B2; STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS;

EID: 79953003027     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.177147     Document Type: Article

References (32)

1. 2 receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J Pharmacol Exp Ther 297:19-26.
2. Bachvarov DR, Saint-Jacques E, Larriveé JF, Levesque L, Rioux F, Drapeau G, and Marceau F (1995) Cloning and pharmacological characterization of the rabbit bradykinin B2 receptor. J Pharmacol Exp Ther 275:1623-1630. (Pubitemid 26130650)
3. Bas M, Greve J, Stelter K, Bier H, Stark T, Hoffmann TK, and Kojda G (2010) Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 56:278-282.
4. 2 receptors. Br J Pharmacol 158:1375-1386.
5. 2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging. Peptides 29:1626-1630.
6. 1 receptors: pharmacologic characterization and application to the study of agonistinduced receptor translocation and cell surface receptor expression. J Pharmacol Exp Ther 329:159-168.
7. 8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. J Pharmacol Exp Ther 323:534-546.
8. Bernier V, Lagacé M, Lonergan M, Arthus MF, Bichet DG, and Bouvier M (2004) Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol 18:2074-2084. (Pubitemid 39006510)
9. Blaukat A, Alla SA, Lohse MJ, and Müller-Esterl W (1996) Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J Biol Chem 271:32366-32374. (Pubitemid 26422278)
10. Blaukat A, Herzer K, Schroeder C, Bachmann M, Nash N, and Müller-Esterl W (1999) Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation. Biochemistry 38:1300-1309.
11. 2 receptor in vivo phosphorylation sites and their role in receptor function. J Biol Chem 276:40431-40440.
12. 2 receptor in a tetracycline-inducible stable HEK293S cell line. Protein Expr Purif 55:300-311.
13. Ceresa BP, Lotscher M, and Schmid SL (2001) Receptor and membrane recycling can occur with unaltered efficiency despite dramatic Rb5(Q79L)-induced changes in endosome geometry. J Biol Chem 276:9649-9654.
14. Gainer JV, Morrow JD, Loveland A, King DJ, and Brown NJ (1998) Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285-1292. (Pubitemid 28496194)
15. Garcia-Perez A and Smith WL (1984) Apical-basolateral membrane asymmetry in canine cortical collecting tubule cells. Bradykinin, arginine vasopressin, prostaglandin E2 interrelationships. J Clin Invest 74:63-74. (Pubitemid 14086045)
16. Gera L, Stewart JM, Whalley ET, Burkard M, and Zuzack JS (1996) New bradykinin antagonists having high potency at B1 receptors. Immunopharmacology 33:183-185. (Pubitemid 26247928)
17. Grosshans BL, Ortiz D, and Novick P (2006) Rabs and their effectors: achieving specificity in membrane traffic. Proc Natl Acad Sci USA 103:11821-11827. (Pubitemid 44215770)
18. Hamdan FF, Rochdi MD, Breton B, Fessart D, Michaud DE, Charest PG, Laporte SA, and Bouvier M (2007) Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between β-arrestins and AP-2. J Biol Chem 282:29089-29100. (Pubitemid 350043377)
19. 2 bradykinin receptors. Mol Pharmacol 45:1-8.
20. Koumbadinga GA, Bawolak MT, Marceau E, Adam A, Gera L, and Marceau F (2010a) Ligand-based approaches to investigate the expression of angiotensin converting enzyme in intact human umbilical vein endothelial cells. Peptides 31:1546-1554.
21. 1 receptor expression in human vascular cells. Eur J Pharmacol 647:117-125.
22. 2 receptors endogenously expressed in HEK293 cells. Biochem Pharmacol 77:269-276.
23. 1 receptor. Br J Pharmacol 131:885-892.
24. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, and Zuraw BL (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57:27-77.
25. Morissette G, Couture JP, Désormeaux A, Adam A, and Marceau F (2008) Lack of direct interaction between enalaprilat and the kinin B1 receptors. Peptides 29:606-612.
26. Morissette G, Houle S, Gera L, Stewart JM, and Marceau F (2007) Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br J Pharmacol 150:369-379. (Pubitemid 46221045)
27. Munoz CM and Leeb-Lundberg LM (1992) Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradation pathways. J Biol Chem 267:303-309.
28. 2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem 274:12738-12747.
29. 2 receptor antagonist. Immunopharmacology 43:187-194.
30. 2 receptor antagonist icatibant. J Am Acad Dermatol 63:913-914.
31. Simaan M, Bédard-Goulet S, Fessart D, Gratton JP, and Laporte SA (2005) Dissociation of β-arrestin from internalized bradykinin B2 receptor is necessary for receptor recycling and resensitization. Cell Signal 17:1074-1083. (Pubitemid 40933528)
32. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P, and Clauser E (1991) Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem 266:5540-5546. (Pubitemid 21909527)